Research Article

Elevated Serum Level of Cytokeratin 18 M65ED Is an Independent Indicator of Cardiometabolic Disorders

Lingling Qian,1,2 Lei Zhang,1 Liang Wu,1 Jing Zhang,1 Qichen Fang,1 Xuhong Hou,1 Qiongmei Gao,1 Huating Li,1 and Weiping Jia1

1Department of Endocrinology and Metabolism, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Clinical Center of Diabetes, Shanghai 200233, China
2Department of Medicine, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

Correspondence should be addressed to Huating Li; huarting99@sjtu.edu.cn and Weiping Jia; wpjia@sjtu.edu.cn

Received 24 July 2019; Revised 17 February 2020; Accepted 28 February 2020; Published 31 March 2020

Academic Editor: Michaelangela Barbieri

Copyright © 2020 Lingling Qian et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Recent studies have suggested that cell death might be involved in the pathophysiology of metabolic disorders. The cytokeratin 18 (CK18) fragment, as a cell death marker, plays an important role in nonalcoholic fatty liver disease (NAFLD). However, only a limited number of studies have found elevated serum levels of CK18 in patients with type 2 diabetes. Moreover, no studies have been conducted yet to investigate the role of CK18 in hypertension or dyslipidemia. In particular, CK18 M65ED is a more sensitive marker of cell death, and its role in cardiometabolic disorders has not been revealed yet.

Methods. A total of 588 subjects were enrolled from the local communities of Shanghai. Serum CK18 M65ED were determined using the enzyme-linked immunosorbent assay. A cardiometabolic disorder was identified by the presence of at least one of the components including overweight or central obesity, diabetes, dyslipidemia, and hypertension.

Results. Subjects with cardiometabolic disorders exhibited significantly higher serum levels of CK18 M65ED than those without cardiometabolic disorders (197.36 (121.13 – 354.50) U/L versus 83.85 (52.80 – 153.75) U/L, respectively, \( P < 0.001 \)). Increased serum CK18 M65ED quartiles were associated with the increased prevalence of cardiometabolic disorders and its components (all \( P < 0.001 \) for all components).

Multiple stepwise regression analysis also revealed that diastolic blood pressure, glycated hemoglobin A1c, alanine transaminase, and high-density lipoprotein cholesterol were independently correlated with serum CK18 M65ED levels (all \( P < 0.01 \)). In addition, logistic regression analysis showed that the serum CK18 M65ED levels were positively correlated with cardiometabolic disorders and in an independent manner. Further, CK18 M65ED was revealed to be an indicator of cardiometabolic disorders in a NAFLD-independent manner.

Conclusions. Elevated levels of CK18 M65ED, a sensitive cell death marker, were independently and positively correlated with cardiometabolic disorders, even after the adjustment for the presence of NAFLD and other cardiovascular risk factors.

1. Introduction

Cardiovascular disease (CVD) remains the leading cause of death and disability in developed countries, and it accounted for the death of approximately 17 million people worldwide in 2013 [1]. Cardiometabolic disorders, including obesity, type 2 diabetes (T2D), insulin resistance (IR), hypertension, and dyslipidemia, are common risk factors for CVD [2]. Moreover, the steady increase in the occurrence of cardiometabolic disorders compels the search for the involved pathophysiology and more effective preventive strategies.
in cardiometabolic diseases [10], and decreased myocardial levels of apoptosis were found to significantly reduce obesity-associated cardiomyopathy [11]. The cellular content of the soluble fraction of CK18 has been shown to be released into the extracellular space during cell death both in vitro and in vivo [12]. A recent study indicated that CK18 played a role in apoptosis, which may be mediated via a feedback regulation loop and may involve regulation of transcription and alternative splicing of a number of genes in NF-κB pathway and certain apoptosis pathways [13]. In addition to caspase-induced apoptosis, other forms of cell death can lead to the release of CK18. For example, CK18 is released during pyroptosis, nonlethal processes of apoptosis independent of caspase activation, or secondary lysis following programmed cell death [14, 15].

However, limited studies have focused on the role of serum CK18 in nonalcoholic fatty liver disease (NAFLD) and cardiometabolic disorders. Serum CK18 was found to be closely associated with hepatic inflammation in patients with NAFLD [16–18]. Chang et al. found that elevated levels of CK18 (assessed by M30 and M65 assays) in patients with T2D had a significant positive association with fasting plasma glucose levels, and it was independent of NAFLD status [19]. Tan et al. demonstrated the correlation between elevated levels of CK18 M30 and IR in patients with polycystic ovarian syndrome [20]. Civera et al. showed that increased insulin resistance induces an increase in the levels of CK18 M30 in patients with severe obesity [21]. M30 was highly correlated to diastolic dysfunction indices in adolescents with obesity [22]. However, the role of CK18 in hypertension or dyslipidemia in adults has not been studied yet. Furthermore, the association between serum CK18 M65ED levels and cardiometabolic disorders has also not been investigated. In the present study, we therefore investigated this association with a focus on cardiometabolic disorders including overweight or central obesity, diabetes, dyslipidemia, and hypertension.

2. Methods

2.1. Study Participants. Subjects aged 18 years or older were enrolled from the local communities in Shanghai. All subjects underwent comprehensive physical examinations, routine biochemical analyses of blood, 75 g oral glucose tolerance test, hepatitis B surface antigen test, hepatitis C virus antibody test, and B-ultrasonography. The histories of present and past illnesses, medical therapy, and alcohol consumption were obtained through standard questionnaires. Subjects with the following conditions were excluded from this study: biliary obstructive disease, acute or chronic viral hepatitis, drug-induced liver disease, autoimmune hepatitis, Wilson’s disease, known hyperthyroidism or hypothyroidism, presence of cancer, ongoing treatment with systemic corticosteroids, pregnancy, and current drinkers and exdrinkers. A total of 588 subjects were enrolled in the study. Of them, 310 had cardiometabolic disorders, and the control group consisted of 278 age-matched participants without conditions of obesity, central obesity, diabetes, dyslipidemia, or hypertension. The study was approved by the Ethics Committee of Shanghai Jiao Tong University Affiliated Sixth People’s Hospital and was conducted in accordance with the principles of the declaration of Helsinki. All data were handled without compromising the privacy of the study participants. All participants provided written informed consent prior to enrollment.

2.2. Anthropometric and Laboratory Measurements. Blood pressure, weight, height, waist circumference (WC), and biochemical indices were measured according to our previous standardized protocols [23]. Body mass index (BMI) = weight (kg)/height² (m²). Blood samples collected from the subjects following an overnight fast of at least 10h were tested to measure the levels of serum fasting plasma glucose (FPG), fasting insulin (FINS), glycated hemoglobin A1c (HbA1c), alanine transaminase (ALT), aspartame transferase (AST), gamma-glutamyl-transferase (GGT), triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C). The 2-hour plasma glucose (2hPG) levels were measured following a 75g oral glucose tolerance test (OGTT). Basal insulin secretion and insulin sensitivity were calculated using the homeostasis model assessment (HOMA) calculations: HOMA−B = [(FINS) (µU/L) × 6 − 3.33]/[FPG (mmol/L) − 3.5] and HOMA−IR = FINS × FPG/22.5 [23]. The concentration of serum CK18 M65ED was quantified using the M65 EpiDeath enzyme-linked immunosorbent assay kit (Peviva AB, Bromma, Sweden). As shown in Figure 1, the difference between CK M30 assay, CK M65 assay, and CK M65ED assay was explained. We chose the M65ED assay in this present study as a more sensitive marker for cell death. The intra- and interassay variations for the measurement of CK18 M65ED were 5.23% and 7.12%, respectively.

Cytokeratin 18 is a major intermediate filament protein of the cytoskeleton that is expressed in simple epithelial cells, hepatocytes, cholangiocytes, pancreas, and colon [16, 24, 25]. During apoptosis, full-length CK18 can be cleaved at two sites into three fragments [26]. The M30 assay can detect the caspase-cleaved fragments of CK18 by using the monoclonal antibody, M30, showing the extent of apoptosis [24]. The CK18 M65 assay uses the capture antibody M6 and the detection antibody M5 that are directed against two different epitopes of CK18 and can recognize both full-length CK18 and cleaved fragments of CK18, regardless of whether they are cleaved by caspases or not [18]. The M65ED assay uses the M6 antibody for detection and the M5 as a capture antibody, which can achieve improved binding specificity and lower signals in healthy controls [24, 27].

2.3. Diagnostic Criteria. Cardiometabolic disorders were identified by the presence of at least one of the components including overweight or central obesity, diabetes, dyslipidemia, and hypertension [28]. An overweight condition was defined as a BMI between 25.0 and 29.9 kg/m², and obesity was defined as a BMI ≥ 30 kg/m² [29]. Central obesity was defined as a waist circumference ≥ 90 cm for Chinese men and ≥ 80 cm for Chinese women [30]. For diabetes, a self-reported diagnosis of diabetes determined previously by a health care professional was considered
in addition to FPG ≥ 7.0 mmol/L, 2hPG ≥ 11.1 mmol/L during OGTT, HbA1c ≥ 6.5%, subjects with classic symptoms of hyperglycemia or hyperglycemic crisis, and random plasma glucose ≥ 11.1 mmol/L [31]. Dyslipidemia condition was defined as the levels of TC ≥ 6.20 mmol/L, TG ≥ 2.26 mmol/L, HDL – C < 1.03 mmol/L, and LDL – C ≥ 4.13 mmol/L, or taking lipid-lowering medications [32]. Hypertension condition was defined as a systolic blood pressure (SBP) ≥ 140 mmHg, diastolic blood pressure (DBP) ≥ 90 mmHg, or taking blood pressure-lowering medications [33]. The guidelines for the diagnosis of NAFLD proposed by the Asia-Pacific Working Party were used [34]. NAFLD was clinically defined as manifestations of B-ultrasonography performed by experienced radiologists, ruling out the drinking habit, and the specific diseases that could result in fatty liver, according to our previous standardized protocols [23].

2.4. Statistical Analysis. All analyses were performed using SPSS 25.0 (Chicago, IL, USA). Normally distributed data were expressed as mean ± SD. Data that were not normally distributed were log-transformed before analysis and expressed as median with interquartile range. Categorical variables were expressed as a percentage (%). Student’s unpaired t-test and chi-square test were used for comparison between two groups. Analyses were performed separately for different genders and different components of cardiometabolic disorders. Pearson’s correlation and multiple stepwise regression analysis were used to examine the associations between serum CK18 M65ED levels and various parameters. Multiple logistic regression was used to assess the association of serum CK18 M65ED levels with the risk for cardiometabolic disorders. Serum CK18 M65ED levels were entered in the following two ways: as quartiles and as a continuous variable. The odds ratio (OR) was calculated to determine whether the relevant factors were risk factors for cardiometabolic disorders. The number of cardiometabolic disorders for each subject was indicative of the total number of each cardiometabolic disorder component: obesity or central obesity, diabetes, dyslipidemia, and hypertension. Hence, for each cardiometabolic disorder component, the subjects received a 1 if it was present or a 0 if not present. A two-tailed P value < 0.05 was considered indicative of a statistically significant difference.

3. Results

3.1. Clinical Characteristics of the Study Subjects. A total of 588 subjects were enrolled in this study (median age: 40.00 (33.00–49.75) years) and included 340 men and 248 women. Table 1 lists the clinical and laboratory characteristics of the subjects. Subjects with cardiometabolic disorders (n = 310) exhibited higher values for BMI, WC, SBP, DBP, 2hPG, HbA1c, FINS, HOMA-IR, HOMA-B, ALT, AST, GGT, TG, TC, and LDL-C (all P < 0.05) and a lower value for HDL-C (P < 0.001) than those without cardiometabolic disorders (n = 278). Age and FPG did not differ significantly between the two groups (all P > 0.05).

3.2. Serum CK18 M65ED Levels in Different Components of Cardiometabolic Disorders. As shown in Table 1, the median serum CK18 M65ED level for all subjects was 137.54 (76.51–254.39) U/L. The subjects with cardiometabolic disorders showed higher serum CK18 M65ED levels (197.36 (121.13–354.5)) than those without cardiometabolic disorders (83.85 (52.8–153.75) U/L) (P < 0.001). There was a significant difference in the serum CK18 M65ED levels between men and women with and without cardiometabolic disorders (211.60 (132.53–361.30) U/L versus 74.70 (48.22–136.57) U/L in men, respectively, P < 0.001 and 161.96 (98.33–301.95) U/L versus 96.10 (60.83–158.93) U/L in women, respectively, P < 0.001; Figure 2(a)). Serum CK18 M65ED levels were higher in subjects with obesity or central obesity (202.86 (124.18–350.75) U/L) than non-obese subjects (93.66 (57.82–160.6) U/L). Serum CK18 M65ED levels were higher in subjects with diabetes (279.63 (151.59–457.59) U/L) than nondiabetic subjects (124.43 (69.47–223.53) U/L). Serum CK18 M65ED levels were higher in the subjects with dyslipidemia (233.98 (152.82–371.84) U/L) than those without dyslipidemia (103.41 (60.89–184.01) U/L). Serum CK18 M65ED levels were higher in the subjects suffering from hypertension
Table 1: Characteristics of subjects with and without cardiometabolic disorders.

| Variables                          | Total          | Without cardiometabolic disorders | With cardiometabolic disorders | P value without CD vs. with CD |
|------------------------------------|----------------|------------------------------------|--------------------------------|--------------------------------|
| n (male/female)                    | 588 (340/248)  | 278 (109/169)                      | 310 (231/79)                   | <0.001                         |
| Age (years)                        | 40.0 (33.0–49.8) | 40.0 (32.0–47.0)                  | 40.0 (34.0–52.0)               | 0.101                          |
| Body mass index (kg/m²)            | 24.8 (22.1–27.9) | 22.2 (20.4–23.6)                  | 27.7 (25.4–30.4)               | <0.001                         |
| Waist circumference (cm)           | 86.5 (72.0–97.5) | 71.0 (66.0–77.0)                  | 96.7 (90.6–103.0)              | <0.001                         |
| Systolic blood pressure (mmHg)     | 118 (110–124)  | 114 (109–120)                     | 120 (112–128)                  | <0.001                         |
| Diastolic blood pressure (mmHg)    | 80 (72–82)     | 76 (70–80)                        | 80 (74–85)                     | <0.001                         |
| Fasting plasma glucose (mmol/L)    | 5.08 (4.72–5.58)| 4.96 (4.63–5.27)                 | 5.28 (4.84–5.98)               | 0.251                          |
| 2-hour plasma glucose (mmol/L)     | 6.69 (5.61–8.12)| 5.69 (4.93–6.58)                 | 7.71 (6.70–9.82)               | <0.001                         |
| Fasting insulin (µU/mL)            | 10.10 (5.28–13.10)| 5.51 (3.93–8.51)                | 12.65 (10.99–16.73)            | <0.001                         |
| HOMA-IR                            | 2.26 (1.18–3.23)| 1.21 (0.85–1.89)                 | 3.10 (2.49–4.39)               | <0.001                         |
| HOMA-B                             | 30.57 (16.92–49.4)| 21.81 (13.88–34.93)            | 41.04 (28.37–64.9)             | 0.001                          |
| Alanine aminotransferase (IU/L)    | 21 (13–33)     | 14 (10.75–19.00)                  | 29 (20–43)                     | <0.001                         |
| Aspartate transaminase (IU/L)      | 20 (17–25)     | 18 (16–21)                        | 22 (19–28)                     | <0.001                         |
| Gamma-glutamyl-transferase (IU/L)  | 24 (15–40)     | 16 (13–24)                        | 37 (24–49)                     | <0.001                         |
| Triglycerides (mmol/L)             | 1.31 (0.89–1.86)| 1.01 (0.72–1.30)                 | 1.74 (1.28–2.38)               | <0.001                         |
| Total cholesterol (mmol/L)         | 4.75 ± 0.86    | 4.42 ± 0.73                       | 5.04 ± 0.85                    | <0.001                         |
| HDL cholesterol (mmol/L)           | 1.21 (1.05–1.4) | 1.37 (1.23–1.57)                 | 1.08 (0.95–1.21)               | <0.001                         |
| LDLC cholesterol (mmol/L)          | 2.94 ± 0.73    | 2.73 ± 0.62                       | 3.12 ± 0.77                    | <0.001                         |

Data are mean ± SD or median (interquartile range). *Log transformed before analysis. CD: cardiometabolic disorders; HbA1c: glycated hemoglobin A1c; HDL: high-density lipoprotein; LDL: low-density lipoprotein.

(291.61 (182.44–460.18) U/L) than those not suffering from hypertension (124.58 (69.7–218.12) U/L) (all P < 0.001; Figure 2(b)).

3.3. Clinical Characteristics and Prevalence of Cardiometabolic Disorders Stratified by Quartiles of Serum CK18 M65ED Levels. The CK18 M65ED quartiles were defined according to the median and interquartile values for the serum CK18 M65ED levels for the entire study population as follows: quartile 1, ≤76.51 U/L (n = 147); quartile 2, 76.51–137.54 U/L (n = 147); quartile 3, 137.54–254.39 U/L (n = 147); and quartile 4, ≥254.39 U/L (n = 147). Clinical parameters, such as BMI, WC, SBP, DBP, FPG, 2hPG, HbA1c, HOMA-IR, ALT, AST, GGT, TG, TC, and LDL-C, displayed an increasing trend from quartile 1 to quartile 4 (all P < 0.001; Table 2). However, HDL-C displayed a decreasing trend from quartile 1 to quartile 4 (P < 0.001; Table 2). In addition, the prevalence of cardiometabolic disorders and its components (obesity, central obesity, diabetes, dyslipidemia, and hypertension) increased from quartile 1 to quartile 4 (all P < 0.001; Table 2). As shown in Table 2 and Figure 3, the number of cardiometabolic disorder components also increased from quartile 1 to quartile 4.

3.4. Association of Clinical Parameters with Serum CK18 M65ED Levels. Pearson’s correlation analysis revealed positive correlations between BMI, WC, SBP, DBP, FPG, 2hPG, HbA1c, HOMA-IR, ALT, AST, GGT, TG, TC, and LDL-C, and serum CK18 M65ED levels (all P < 0.001) (Table 3). HDL-C showed a negative correlation with serum CK18 M65ED levels. To further identify factors independently affecting serum CK18 M65ED levels, we performed stepwise regression analysis with the serum CK18 M65ED levels designated as the dependent variable and BMI, WC, SBP, DBP, FPG, 2hPG, HbA1c, HOMA-IR, ALT, AST, GGT, TG, TC, HDL-C, and LDL-C levels designated as the independent variables, with the adjustment for gender. The analysis revealed that the levels of DBP (standardized β = 0.207), HbA1c (standardized β = 0.171), ALT (standardized β = 0.474), and HDL-C (standardized β = −0.135) were independently associated with serum CK18 M65ED levels (all P < 0.01).

3.5. Serum CK18 M65ED Is an Independent Risk Factor for Cardiometabolic Disorders. We performed a binary logistic regression analysis in which the presence of cardiometabolic disorders was designated as the dependent variable in three different models, and adjustments were made for age, gender, BMI, and other related clinical parameters. The multivariable-adjusted (age, gender, and BMI, model 1) OR of cardiometabolic disorders across the quartiles of CK18 M65ED were 1.00 (95% confidence interval (CI), 1.00–1.00), 2.77 (95% CI, 1.31–5.85), 3.14 (95% CI, 1.43–6.89), and 9.08 (95% CI, 3.91–21.08) (all P < 0.001) (Table 4). The association was still significant (P = 0.012) after further adjustment for SBP, DBP, ALT, AST, GGT, TG, TC, HDL-C, LDL-C, HOMA-IR, HOMA-B, and HbA1c (model 2).
and maintained significant difference ($P = 0.018$) after adjustment for SBP, DBP, ALT, AST, GGT, TG, TC, HDL-C, LDL-C, FPG, 2hPG, HbA1c, and FINS (model 3). Considering that CK18 levels are elevated in NAFLD, we adjusted the binary variable of NAFLD with age and gender, and still observed significant association ($P = 0.011$, model 4), suggesting that the association of CK18 with cardiometabolic disorders is independent of NAFLD. Upon examining CK18 M65ED levels as a continuous variable, each 1 SD increase in the CK18 M65ED levels was a positive predictor of cardiometabolic disorders (all $P < 0.05$) with the adjustment of different variables in different models.

### 4. Discussion

In the present study, we have demonstrated that serum CK18 M65ED levels are significantly increased in Chinese subjects with multiple cardiometabolic disorders and these levels positively correlate with DBP, HbA1c, ALT, and HDL-C levels. Our analyses showed that increased serum CK18 M65ED levels is an independent risk factor for cardiometabolic disorders, after accounting for general cardiometabolic risk parameters or the presence of NAFLD. Additionally, we found that the prevalence of cardiometabolic disorders and its components increased with increasing quartiles of CK18 M65ED.

Several studies have been conducted to assess serum CK18 levels in NAFLD, as it is one of the most extensively evaluated biomarkers of steatohepatitis [35]. However, to our knowledge, limited studies have examined the association between serum CK18 M65ED levels and the risk for cardiometabolic disorders. In accordance with the results of Tan et al. and Civera et al., we showed that CK18 M65ED is positively correlated with the insulin resistance index of HOMA-IR [20, 21]; however, the correlation was not observed in the multiple stepwise regression analysis. The CK18 M65ED levels positively correlated with fasting glucose levels, and it was associated with cardiometabolic disorders independent of NAFLD status, which is in agreement with the results of Chang et al. [19]. In addition to adult hepatocytes [16], CK18 can be expressed in simple epithelial cells, cholangiocytes, pancreas, and colon [16, 24, 25]. CK18 M65ED can act as a cell death marker in cardiometabolic disorders because of its ability to detect both native and intact CK18 [18]. Previous studies have demonstrated that apoptosis can cause a decrease in the number of circulating mucosal-associated invariant T cells in cardiometabolic diseases [7]. Moreover, myocardial cells undergo death in obesity-associated cardiomyopathy in high-fat diet-fed mice [8]. In the present study, we extend these investigations by providing further evidences of the possibility of cell death in cardiometabolic disorders.

The strong correlation between serum CK18 M65ED levels and the risk for cardiometabolic disorders might be explained by the interactions among various metabolic stress inducers that are activated by nutritional surplus, inflammation, innate immune system, and gut microbiota during the induction of cell death. Under conditions of glucotoxicity, lipotoxicity, and exposure to proinflammatory cytokines or biologically active sphingolipids, cell death mediated by ER stress, 4-hydroxynonenal, and endogenous reactive oxygen species may contribute to the pathogenesis of cardiometabolic disorders [9, 10, 36]. Long-lasting and low-grade chronic inflammation mediated by cytokines and chemokines, which are primarily released by innate immune cells under cardiometabolic stress, is a distinguishing feature of
| Variables                              | Serum CK18 M65ED quartiles | P for trend |
|---------------------------------------|----------------------------|-------------|
|                                       | Quartile 1 | Quartile 2 | Quartile 3 | Quartile 4 |
| n (male/female)                      | 71/76      | 74/73      | 90/57      | 105/42      |
| Age (years)§                         | 39 (33–45) | 42 (34–52) | 40 (34–48) | 38 (32–52)  |
| Body mass index (kg/m²)§             | 22.8 (20.8–24.5) | 24.1 (21.8–26.6) | 25.9 (22.9–29.3) | 27.4 (24.5–30.5) |
| Waist circumference (cm)§             | 76.0 (67.0–86.0) | 81.0 (71.0–95.0) | 90.1 (73.0–100.0) | 95.0 (87.6–102.9) |
| Systolic blood pressure (mmHg)§       | 112.0 (108.5–120.0) | 116.0 (109.0–124.0) | 119.0 (110.0–125.0) | 120.0 (114.0–128.5) |
| Diastolic blood pressure (mmHg)§      | 75 (70–80) | 78 (71–80.5) | 80 (73.8–84) | 80 (76–85)  |
| Fasting plasma glucose (mmol/L)§      | 5.98 (5.16–7.21) | 6.56 (5.44–8.05) | 6.80 (5.67–8.18) | 7.72 (6.49–10.42) |
| HbA1c (%)§                           | 5.5 (5.3–5.7) | 5.5 (5.3–5.8) | 5.6 (5.4–5.8) | 5.7 (5.4–6.8) |
| Fasting insulin (μU/mL)§              | 6.50 (4.60–11.58) | 8.40 (5.09–12.30) | 10.69 (5.24–13.79) | 11.90 (10.16–16.71) |
| HOMA-IR§                             | 1.42 (1.02–2.48) | 1.80 (1.11–2.86) | 2.44 (1.16–3.44) | 2.94 (2.38–4.78) |
| HOMA-B§                              | 26.21 (16.27–48.58) | 29.41 (15.47–43.94) | 30.97 (15.91–57.90) | 36.34 (22.78–55.74) |
| Alanine aminotransferase (IU/L)§      | 14 (11–20) | 16 (15.7–23) | 22 (14–35) | 41 (24–62)  |
| Aspartate transaminase (IU/L)§        | 18 (16–21) | 18 (16–22) | 21 (17–25) | 27 (21–32)  |
| Gamma-glutamyl-transferase (IU/L)§    | 17 (13–26) | 19.5 (14–28) | 31 (17–41) | 40 (24–56)  |
| Triglycerides (mmol/L)§               | 1.08 (0.77–1.45) | 1.17 (0.79–1.69) | 1.49 (1.03–2.15) | 1.74 (1.14–2.38) |
| Total cholesterol (mmol/L)§           | 4.48 ± 0.81 | 4.69 ± 0.84 | 4.82 ± 0.84 | 4.99 ± 0.85  |
| HDL cholesterol (mmol/L)§             | 1.31 (1.20–1.48) | 1.28 (1.11–1.47) | 1.13 (0.97–1.35) | 1.10 (0.95–1.21) |
| LDL cholesterol (mmol/L)§             | 2.77 ± 0.70 | 2.90 ± 0.69 | 2.97 ± 0.72 | 3.12 ± 0.76  |
| Cytokeratin 18 M65 (U/L)§             | 53.00 (43.08–62.25) | 104.69 (87.88–120.78) | 175.22 (155.98–210.06) | 412.52 (321.94–594.20) |
| Cardiometabolic disorders (n, %)      | 29 (19.73%) | 70 (47.62%) | 90 (61.22%) | 121 (82.31%) |
| Obesity (n, %)                        | 4 (2.72%) | 11 (7.48%) | 28 (19.05%) | 45 (30.61%)  |
| Central obesity (n, %)                | 25 (17.01%) | 59 (40.14%) | 81 (55.1%) | 107 (72.79%) |
| Diabetes (n, %)                       | 1 (0.68%) | 14 (9.52%) | 19 (12.93%) | 42 (28.57%)  |
| Dyslipidemia (n, %)                   | 2 (1.36%) | 29 (19.73%) | 65 (44.22%) | 78 (53.06%)  |
| Hypertension (n, %)                   | 1 (0.68%) | 12 (8.16%) | 20 (13.61%) | 38 (25.85%)  |
| No. of CD components                  | ONE MORE (n, %) | 29 (19.73%) | 70 (47.62%) | 90 (61.22%) |
| Two more (n, %)                       | 0 (0%) | 29 (19.73%) | 67 (45.58%) | 90 (61.22%)  |
| Three more (n, %)                     | 0 (0%) | 11 (7.48%) | 22 (14.97%) | 38 (25.85%)  |
| Four (n, %)                           | 0 (0%) | 4 (2.72%) | 6 (4.08%) | 15 (10.2%)   |

§Log transformed before analysis. CK18: cytokeratin 18; CD: cardiometabolic disorder.
cardiometabolic disorders, and their overactive responses can directly contribute to the pathogenesis of such diseases [37–39]. For example, pancreatic β-cell apoptosis due to hyperglycemia and ER stress can contribute to the decreased β-cell mass that characterizes T2D, and the activation of inflammasomes by these harmful factors can lead to β-cell death [9]. Thus, β-cell death and cell death-associated inflammation interact with each other through innate immune receptors [9]. Another explanation might be that altered microbial compositions in patients with cardiometabolic disorders may foster inflammation by producing more proinflammatory molecules such as lipopolysaccharide and peptidoglycans that can interact with host pattern recognition receptors of the innate immune system [40–42]. Winer et al. have demonstrated that obesity-altered gut microbiome can increase the recruitment of macrophages and reduce the

![Figure 3: Proportions of participants with multiple cardiometabolic disorders according to serum CK18 M65ED quartiles. Histograms are weighted percentages. The number of cardiometabolic disorders for each subject was the total presence number of obesity or central obesity, diabetes, dyslipidemia, and hypertension; that is, for each cardiometabolic disorder component, the participants received a 1 if this disorder was present, and 0 otherwise. CK18: cytokeratin 18.](image)

| Variables                              | Pearson correlation analysis | Multiple stepwise regression analysis |
|----------------------------------------|------------------------------|--------------------------------------|
|                                        | r   | P value | Standardized β | t    | P value a |
| Gender                                 | -0.16 | <0.001 | — | — | — |
| Age (years)                            | 0.01 | 0.806 | — | — | — |
| Body mass index (kg/m²)§               | 0.404 | <0.001 | — | — | — |
| Waist circumference (cm)§              | 0.401 | <0.001 | — | — | — |
| Systolic blood pressure (mmHg)§        | 0.303 | <0.001 | — | — | — |
| Diastolic blood pressure (mmHg)§       | 0.315 | <0.001 | 0.207 | 5.279 | <0.001 |
| Fasting plasma glucose (mmol/L)§       | 0.26 | <0.001 | — | — | — |
| 2-hour plasma glucose (mmol/L)§        | 0.323 | <0.001 | — | — | — |
| HbA1c (%)§                             | 0.234 | <0.001 | 0.171 | 4.526 | <0.001 |
| Fasting insulin (μU/mL)§               | 0.249 | <0.001 | — | — | — |
| HOMA-IR§                               | 0.297 | <0.001 | — | — | — |
| HOMA-B§                                | 0.081 | 0.06 | — | — | — |
| Alanine aminotransferase (IU/L)§       | 0.522 | <0.001 | 0.474 | 10.464 | <0.001 |
| Aspartate transaminase (IU/L)§         | 0.431 | <0.001 | — | — | — |
| Gamma-glutamyl-transferase (IU/L)§     | 0.388 | <0.001 | — | — | — |
| Triglycerides (mmol/L)§                | 0.329 | <0.001 | — | — | — |
| Total cholesterol (mmol/L)             | 0.199 | <0.001 | — | — | — |
| HDL cholesterol (mmol/L)§              | -0.339 | <0.001 | -0.135 | -3.035 | 0.003 |
| LDL cholesterol (mmol/L)               | 0.153 | <0.001 | — | — | — |

§Log transformed before analysis. *Original variables included all the variables with P < 0.05 in the Pearson correlation analysis and were adjusted for gender. CK18: cytokeratin 18; HbA1c: glycated hemoglobin A1c; HDL: high-density lipoprotein; LDL: low-density lipoprotein.
Table 4: Odds ratios of cardiometabolic disorders based on serum cytokeratin 18 M65ED as a continuous or categorical variable.

| M65ED as categories | Model 1a | P | Model 2b | Odds ratios (95% CI) | Model 3c | P | Model 4d | P |
|---------------------|---------|---|----------|---------------------|---------|---|---------|---|
| Quartile 1          | 1.00 (1.00–1.00) | — | 1.00 (1.00–1.00) | —       | 1.00 (1.00–1.00) | — |
| Quartile 2          | 2.77 (1.31–5.85) | 0.008 | 3.41 (1.13–10.29) | 0.03 | 3.24 (1.00–10.44) | 0.049 | 4.02 (2.31–7.03) | <0.001 |
| Quartile 3          | 3.14 (1.43–6.89) | 0.004 | 3.74 (1.00–13.95) | 0.049 | 4.96 (1.20–20.47) | 0.027 | 6.64 (3.79–11.65) | <0.001 |
| Quartile 4          | 9.08 (3.91–21.08) | <0.001 | 14.28 (2.79–73.21) | 0.001 | 16.83 (2.75–103.19) | 0.002 | 18.39 (9.89–34.21) | <0.001 |
| P for trend         | <0.001 | 0.012 | —         | 0.018 | —         | <0.001 |
| M65ED (per 1 SD)    | 1.92 (1.39–2.65) | <0.001 | 1.90 (1.13–3.19) | 0.015 | 1.97 (1.11–3.48) | 0.020 | 2.75 (2.07–3.66) | <0.001 |

*Model 1 adjusted for age, gender, and BMI. *Model 2 adjusted for variables in model 1 and also for SBP, DBP, ALT, AST, GGT, TG, TC, HDL-C, LDL-C, HOMA-IR, HOMA-B, and HbA1c. *Model 3 adjusted for variables in model 1 and also for SBP, DBP, ALT, AST, GGT, TG, TC, HDL-C, LDL-C, FPG, 2hPG, HbA1c, and FINS. *Model 4 adjusted for age, gender, and nonalcoholic fatty liver disease (yes, no). Serum cytokeratin 18 M65ED levels: quartile 1: 76.51 U/L; quartile 2: 76.51–137.54 U/L; quartile 3: 137.54–254.39 U/L; quartile 4: ≥254.39 U/L. CI: confidence interval; SD: standard deviation.

5. Conclusions

In this study, the serum levels of CK18 M65ED, as a cell death marker, were significantly increased among subjects with cardiometabolic disorders, and these increased levels were associated with the risk for cardiometabolic disorders, independent of other cardiometabolic risk parameters, and NAFLD. Our study suggested that elevated serum CK18 M65ED levels could be used to predict the risk for cardiometabolic disorders.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Ethical Approval

The study was approved and supervised by the Ethics Committee of Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, following the principles of the declaration of Helsinki. All subjects provided written informed consent.

Conflicts of Interest

The authors declare that they have no competing interests.

Acknowledgments

This work was supported by the National Natural Science Foundation major international (regional) joint research project of China (grant number 81220108006) and National Natural Science Foundation Council-National Health and Medical Research Council joint research grant of China (grant number 81561128016) to Weiping Jia, General Program of Natural Science Foundation of China (grant number 81870598), Shanghai Pujiang Program (grant number 17PJ1407500), and Municipal Human Resources Development Program for Outstanding Young Talents in Medical and Health Sciences in Shanghai of China (grant number 2017YQ009) to Huating Li. We are very grateful to all of the involved clinicians, nurses, and technicians for dedicating their time and skill for helping with the present study.
References

[1] GBD 2013 Mortality and Causes of Death Collaborators, I. I. Abubakar, T. Tillmann, and A. Banerjee, "Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013," Lancet, vol. 385, no. 9963, pp. 117–171, 2015.

[2] D. Mozaffarian, E. J. Benjamin, A. S. Go et al., "Heart disease and stroke statistics-2016 update: a report from the American Heart Association," Circulation, vol. 133, no. 4, pp. e38–360, 2016.

[3] L. Ozcan and I. Tabas, "Role of endoplasmic reticulum stress in metabolic disease and other disorders," Annual Review of Medicine, vol. 63, no. 1, pp. 317–328, 2012.

[4] S. Dalleau, M. Baradat, F. Guéraud, and L. Huc, "Cell death and diseases related to oxidative stress:4-hydroxynonenal (HNE) in the balance," Cell Death and Differentiation, vol. 20, no. 12, pp. 1615–1630, 2013.

[5] K. S. T'wayana and P. Ravan, "Eukaryotic cell survival mechanisms: disease relevance and therapeutic intervention," Life Sciences, vol. 205, pp. 73–90, 2018.

[6] A. Swisa, B. Glaser, and Y. Dor, "Metabolic stress and compromised identity of pancreatic beta cells," Frontiers in Genetics, vol. 8, 2017.

[7] S. Gezginci-Oktayoglu, E. Onay-Ucar, S. Sancar-Bas, A. Karatug-Kacar, E. S. N. Arda, and S. Bolkent, "Involvement of dying beta cell originated messenger molecules in differentiation of pancreatic mesenchymal stem cells under gluotoxic and glucolipotoxic conditions," Journal of Cellular Physiology, vol. 233, no. 5, pp. 4235–4244, 2018.

[8] R. Guardado Mendoza, C. Perego, G. Finzi et al., "Delta cell death in the islet of Langerhans and the progression from normal glucose tolerance to type 2 diabetes in non-human primates (baboon, Papio hamadryas)," Diabetologia, vol. 58, no. 8, pp. 1814–1826, 2015.

[9] J. Guo, Z. Wang, J. Wu et al., "Endothelial SIRT6 is vital to prevent hypertension and associated cardioirenal injury through targeting Nkx3.2-GATA3 signaling," Circulation Research, vol. 124, no. 10, pp. 1448–1461, 2019.

[10] S. Touch, K. E. Assmann, J. Aron-Wisnewsky et al., "Mucosal-associated invariant T (MAIT) cells are depleted and prone to apoptosis in cardiometabolic disorders," FASEB Journal, vol. 32, no. 9, pp. 5078–5089, 2018.

[11] H. Tronchere, M. Cinato, A. Timotin et al., "Inhibition of PIKfyve prevents myocardial apoptosis and hypertrophy through activation of SIRT3 in obese mice," EMBO Molecular Medicine, vol. 9, no. 6, pp. 770–785, 2017.

[12] M. Hesse, T. M. Magin, and K. Weber, "Genes for intermediate filament proteins and the draft sequence of the human genome: novel keratin genes and a surprisingly high number of pseudogenes related to keratin genes 8 and 18," Journal of Cell Science, vol. 114, no. 14, pp. 2569–2575, 2001.

[13] Y. Cheng, K. Qin, N. Huang et al., "Cytokeratin 18 regulates the transcription and alternative splicing of apoptotic-related genes and pathways in HeLa cells," Oncology Reports, vol. 42, no. 1, pp. 301–312, 2019.

[14] M. C. Abraham and S. Shaham, "Death without caspases, caspases without death," Trends in Cell Biology, vol. 14, no. 4, pp. 184–193, 2004.

[15] A. Eguchi, A. Wree, and A. E. Feldstein, "Biomarkers of liver cell death," Journal of Hepatology, vol. 60, no. 5, pp. 1063–1074, 2014.

[16] M. B. Omary, N. O. Ku, P. Strnad, and S. Hanada, "Toward unraveling the complexity of simple epithelial keratins in human disease," Journal of Clinical Investigation, vol. 119, no. 7, pp. 1794–1805, 2009.

[17] A. E. Feldstein, A. Wieckowska, A. R. Lopez, Y. C. Liu, N. N. Zein, and A. McCullough, "Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study," Hepatology, vol. 50, no. 4, pp. 1072–1078, 2009.

[18] D. Joka, K. Wahl, S. Moeller et al., "Prospective biopsy-controlled evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic steatohepatitis," Hepatology, vol. 55, no. 2, pp. 455–464, 2012.

[19] Y. H. Chang, H. C. Lin, D. W. Hwu, D. M. Chang, K. C. Lin, and Y. J. Lee, "Elevated serum cytokeratin-18 concentration in patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease," Annals of Clinical Biochemistry, vol. 56, no. 1, pp. 141–147, 2019.

[20] S. Tan, L. P. Bechmann, S. Benson et al., "Apoptotic markers indicate nonalcoholic steatohepatitis in polycystic ovary syndrome," Journal of Clinical Endocrinology & Metabolism, vol. 95, no. 1, pp. 343–348, 2010.

[21] M. Civera, A. Urios, M. L. Garcia-Torres et al., "Relationship between insulin resistance, inflammation and liver cell apoptosis in patients with severe obesity," Diabetes Metabolism Research and Reviews, vol. 26, no. 3, pp. 187–192, 2010.

[22] M. C. Yang, H. K. Liu, Y. T. Su, C. C. Tsai, and J. R. Wu, "Serum apoptotic marker M30 is positively correlated with early diastolic dysfunction in adolescent obesity," PloS One, vol. 14, no. 5, 2019.

[23] H. Li, Q. Fang, F. Gao et al., "Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride," Journal of Hepatology, vol. 53, no. 5, pp. 924–940, 2010.

[24] T. Ueno, M. Toi, and S. Linder, "Detection of epithelial cell death in the body by cytokeratin 18 measurement," Biomedicine & Pharmacotherapy, vol. 59, Supplement 2, pp. S359–S362, 2005.

[25] S. Aho and J. Uitto, "180-kD bullous pemphigoid antigen/type XVII collagen: tissue-specific expression and molecular interactions with keratin 18," Journal of Cellular Biochemistry, vol. 72, no. 3, pp. 356–367, 1999.

[26] B. Schutte, M. Henfling, W. Kölgen et al., "Keratin 8/18 breakdown and reorganization during apoptosis," Experimental Cell Research, vol. 297, no. 1, pp. 11–26, 2004.

[27] L. De Petris, E. Brandén, R. Herrmann et al., "Diagnostic and prognostic role of plasma levels of two forms of cyto-keratin 18 in patients with non-small cell lung cancer," European Journal of Cancer, vol. 47, no. 1, pp. 131–137, 2011.

[28] T. Wang, Z. Zhao, Y. Xu et al., "Insulin resistance and beta-cell dysfunction in relation to cardiometabolic risk patterns," Journal of Clinical Endocrinology & Metabolism, vol. 103, no. 6, pp. 2207–2215, 2018.

[29] World Health Organization, Obesity: preventing and managing the global epidemic May 2019 http://www.who.int/nutrition/publications/obesity_executive_summary.pdf.
The World Health Organization Western Pacific Region, *The Asia-Pacific perspective: redefining obesity and its treatment*, May 2019 http://www.wpro.who.int/nutrition/documents/docs/Redefiningobesity.pdf.

American Diabetes Association, “2. Classification and diagnosis of diabetes:Standards of medical care in diabetes-2018,” *Diabetes Care*, vol. 41, Supplement 1, pp. S13–S27, 2018.

Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults, “Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III),” *Journal of the American Medical Association*, vol. 285, no. 19, pp. 2486–2497, 2001.

A. Chobanian, G. Bakris, H. Black et al., “The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report,” *Journal of the American Medical Association*, vol. 289, no. 19, pp. 2560–2572, 2003.

S. Chitturi, G. C. Farrell, E. Hashimoto et al., “Non-alcoholic fatty liver disease in the Asia-Pacific region: definitions and overview of proposed guidelines,” *Journal of Gastroenterology and Hepatology*, vol. 22, no. 6, pp. 778–787, 2007.

V. W. S. Wong, L. A. Adams, V. de Ledinghen, G. L. H. Wong, and S. Sookoian, “Noninvasive biomarkers in NAFLD and NASH – current progress and future promise,” *Nature Reviews Gastroenterology Hepatology*, vol. 15, no. 8, pp. 461–478, 2018.

I. Tabas and D. Ron, “Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress,” *Nature Cell Biology*, vol. 13, no. 3, pp. 184–190, 2011.

M. Xu, P. P. Liu, and H. Li, “Innate immune signaling and its role in metabolic and cardiovascular diseases,” *Physiological Reviews*, vol. 99, no. 1, pp. 893–948, 2019.

Y. Tang, S. Purkayastha, and D. Cai, “Hypothalamic microinflammation: a common basis of metabolic syndrome and aging,” *Trends in Neurosciences*, vol. 38, no. 1, pp. 36–44, 2015.

G. P. Shi, I. Bot, and P. T. Kovanen, “Mast cells in human and experimental cardiometabolic diseases,” *Nature Reviews Cardiology*, vol. 12, no. 11, pp. 643–658, 2015.

A. S. Neish, “Microbes in gastrointestinal health and disease,” *Gastroenterology*, vol. 136, no. 1, pp. 65–80, 2009.

W. H. Tang, T. Kitai, and S. L. Hazen, “Gut microbiota in cardiovascular health and disease,” *Circulation Research*, vol. 120, no. 7, pp. 1183–1196, 2017.

E. Larsson, V. Tremaroli, Y. S. Lee et al., “Analysis of gut microbial regulation of host gene expression along the length of the gut and regulation of gut microbial ecology through MyD88,” *Gut*, vol. 61, no. 8, pp. 1124–1131, 2012.

D. A. Winer, H. Luck, S. Tsai, and S. Winer, “The intestinal immune system in obesity and insulin resistance,” *Cell Metabolism*, vol. 23, no. 3, pp. 413–426, 2016.

C. Wittenbecher, T. Stambuk, O. Kuxhaus et al., “PlasmaN-Glycans as emerging biomarkers of cardiometabolic risk: a prospective investigation in the EPIC-Potsdam cohort study,” *Diabetes Care*, vol. 43, no. 3, pp. 661–668, 2020.

A. K. N. Z. Iwani, M. Y. Jalaludin, R. M. W. M. Zin et al., “TG : HDL-C Ratio Is a Good Marker to Identify Children Affected by Obesity with Increased Cardiometabolic Risk and Insulin Resistance,” *International Journal of Endocrinology*, vol. 2019, 9 pages, 2019.

A. da Silva, A. P. S. Caldas, H. H. M. Hermsoff et al., “Triglyceride-glucose index is associated with symptomatic coronary artery disease in patients in secondary care,” *Cardiovascular Diabetology*, vol. 18, no. 1, p. 89, 2019.

C. Frithioff-Bojsoe, M. A. V. Lund, U. Lausten-Thomsen et al., “Leptin, adiponectin, and their ratio as markers of insulin resistance and cardiometabolic risk in childhood obesity,” *Pediatric Diabetes*, vol. 21, no. 2, pp. 194–202, 2020.

S. Marta and D. Jacek, “ Branched chain amino acids: passive biomarkers or the key to the pathogenesis of cardiometabolic diseases?,” *Advances in Clinical and Experimental Medicine*, vol. 28, no. 9, pp. 1263–1269, 2019.